Open AccessA Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia
Author(s) -
Manaye Tamrie Derseh,
Kiflom Solomon,
Wasihun Tamene,
Wosenie Beneberu,
Ashagrachew Tewabe Yayehrad,
Abyou Seyfu Ambaye
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s327868
Subject(s) - rivaroxaban , medicine , deep vein , warfarin , thrombosis , pulmonary embolism , quality adjusted life year , cost effectiveness , surgery , atrial fibrillation , risk analysis (engineering)
Deep vein thrombosis and pulmonary embolism are known by the collective name venous thromboembolism. Deep vein thrombosis is the third most common cardiovascular disorder in the world. The disease is also prevalent in Africa including Ethiopia, besides lack of studies that show epidemiology of the disease.